The anti-inflammatory effects of RNS60, developed by Revalesio, will be demonstrated at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) to be held in San Francisco between March 18 and 22.
AAAAI caters to allergy and immunology specialization. It has about 6500 members across the US, Canada and 60 other nations. The solution will facilitate development of low-risk therapies for inflammatory pulmonary diseases.
In the early stages of asthma, the solution reduced inflammatory cytokines, such as interleukin-6, interleukin-4, tumor necrosis factor-á (TNF-á), eotaxin and other cytokines that cause asthma. It also enhanced respiration. The cell culture analysis shows the anti-inflammatory movement of RNS60 by reducing the formation of inflammatory mediators such as C-C chemokine receptor type 3 (CCR3) and interleukin-8. The RNS60 also modulates whole cell conductance. The RNS60 is at present undergoing the Phase I/IIa clinical testing for allergic asthma at Stanford University.
The company has used charge-stabilized nanostructures to modify whole cell conductance via impacts on voltage-gated ion channels and voltage-sensing proteins. This controls the G protein-coupled receptors and emission of cytokines, chemokines and adhesion molecules. These modifications minimize inflammation connected to various diseases, such as neurodegenerative, respiratory and cardiovascular diseases.